Kuno van der Post Ph.D
OmniComm Systems, Inc.
Fort Lauderdale, FL, July 2nd, 2012 – OmniComm Systems, Inc. (OTC: OMCM.OB), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that it has signed an agreement with Larix A/S to support their clinical research needs for a 5 year, 31 site study.
Larix, a full-service Clinical Research Organization (CRO) in Denmark offering assistance in all aspects of clinical trials, provides services within statistics, Data Management (DM), Clinical Research (CR), Pharmacovigilance (PV) and Data Monitoring Committees (DMCs) to pharmaceutical, biotechnology and medical device companies. This partnership will enable Larix to provide their customers with high quality products and services to manage complex clinical trials. Larix will utilize OmniComm’s fully integrated eClinical suite, including Portal, Electronic Data Capture (EDC), and Clinical Data Management System (CDMS).
“Larix was looking for a system which could support paper, EDC and hybrid studies and which could live up to Larix’s quality standards to ensure compliance with regulatory requirements. Furthermore, we wanted a solution that was attractive both from a user‘s point of view and from a cost point of view. We looked at several solutions but decided in the end to go with OmniComm’s eClinical Suite. We believe that the system is flexible and easy to use. We are pleased with this collaboration between Larix and OmniComm.” said Klaus Juel Olsen, CEO.
“We are pleased to have been chosen by this prestigious family founded CRO.” said Stephen Johnson, President and COO of OmniComm. “They’ve become one of the largest Danish CROs based on their strong reputation for good customer service, and we look forward to partnering with them to build on their reputation for providing quality solutions and services.”
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
About Larix A/S
Larix is a family founded, privately owned CRO offering full service (statistics, data management, clinical research, pharmacovigilance) solutions. Larix is located in offices near Copenhagen, and is in the middle of the Medicon Valley region and is tightly connected to the thriving pharmaceutical and biotech activities in this region. Larix was founded in 2001 by Klaus Juel Olsen, who started-up as an independent statistical consultant. From 2003 the company expanded with services within data management and more statisticians. The clinical research service was added in 2008 simultaneously with a QA function. From 2010 the services were broadened to include pharmacovigilance and an additional expansion of the employees made Larix the largest Scandinavian CRO within statistics, data management and medical writing
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.